

Hawaii 1 of 8 top US sites selected to offer Phase 1 Next Generation High Binding Potency Best-in-Class SQ Anti-Amyloid Beta Antibody. Research underway at Hawaii Memory Center & Hawaii Alzheimer's Research Unit June 2024, Honolulu



According to [Prothena website](#), PRX012 is a next-generation, high binding potency antibody, designed to enable subcutaneous dosing on a patient-friendly, convenient administration schedule, potentially providing greater accessibility for patients and caregivers.



Preclinical data have shown that PRX012 binds to beta amyloid plaques and oligomers with high avidity, enabling effective levels of A β plaque occupancy at relatively lower dose ranges, which are optimal for *subcutaneous delivery*. Compared to first generation anti-A β antibodies, PRX012 is expected to result in less variance of antibody concentrations in the brain.



Phase 1, placebo-controlled, single ascending dose clinical trial of an investigational drug called PRX012 in adults aged 60 to 85 with probable Alzheimer's disease (AD) or mild cognitive impairment due to AD.

Qualified patients will get FREE travel & FREE Amyloid PET & must be willing to travel to partner Amyloid PET facility in Los Angeles.



“Our Hawaii patients, caregivers, families, neurologists & researchers are honored to contribute to the development of Next generation Alzheimer's Therapy” Kore Kai Liow, MD, Neurologist & Principal Investigator, [Hawaii Memory Disorders Center](#) & [Alzheimer's Research Unit](#), Clinical Professor of Medicine (Neurology), Graduate Faculty, Clinical & Translational Research, University of Hawai'i John Burns School of Medicine

Dedicated Hawaii Alzheimer's Research Hotline (808) 564-6141